Gadoteridol
Top View
- Manual on Contrast Media Version 7 2010
- Provisional Peer-Reviewed Toxicity Values for Stable (Nonradioactive) Gadolinium (Casrn 7440-54-2) and Soluble Salts
- MEDICATION GUIDE PROHANCE® (Prō-ˈhan(T)S) (Gadoteridol)
- Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Pharmacologyonline 3: 728-781 (2010) Newsletter Bradu and Rossini
- Safety and Clinical Usefulness of Gadoteric Acid Including Post-Marketing Surveillance
- RCR Position Statement on the Revision of Marketing Authorisations
- Repurposing Clinical Agents for Chemical Exchange Saturation Transfer Magnetic Resonance Imaging: Current Status and Future Perspectives
- Gadolinium-Containing Agents Restrictions on Use
- 115-14 Anonymisierter Beschluss
- Special Report the Blood-Brain Barrier
- Gadoteridol) Injection for Intravenous Use What Is PROHANCE? • PROHANCE Is a Prescription Medicine Called a Gadolinium-Based Contrast Agent (GBCA)
- Contrast Dye Poster Back3
- Pharmacokinetics Uses and Administration Adverse Effects And
- 201277Orig1s000
- MRI-CEST Assessment of Tumour Perfusion Using X-Ray Iodinated Agents: Comparison with a Conventional Gd-Based Agent